Valley National Advisers’s GSK GSK Stock Holding History

Valley National Advisers’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.1K	Hold	1,586	–	–	0.01%	346
2026 Q1	$87K	Buy	1,586 +18	+1%	+$975	0.01%	334
2025 Q4	$76K	Buy	1,568 +376	+32%	+$17.5K	0.01%	351
2025 Q3	$51K	Sell	1,192 -376	-24%	-$14.7K	0.01%	377
2025 Q2	$60K	Sell	1,568 -142	-8%	-$5.43K	0.01%	368
2025 Q1	$66K	Buy	1,710 +142	+9%	+$5.2K	0.01%	347
2024 Q4	$53K	Buy	1,568 +200	+15%	+$7.2K	0.01%	350
2024 Q3	$55K	Hold	1,368	–	–	0.01%	347
2024 Q2	$52K	Sell	1,368 -25	-2%	-$1.05K	0.01%	385
2024 Q1	$59K	Buy	1,393 +65	+5%	+$2.68K	0.01%	389
2023 Q4	$49K	Hold	1,328	–	–	0.01%	404
2023 Q3	$48K	Hold	1,328	–	–	0.01%	391
2023 Q2	$48K	Hold	1,328	–	–	0.01%	395
2023 Q1	$49K	Buy	1,328 +289	+28%	+$10.1K	0.01%	385
2022 Q4	$36K	Sell	1,039 -49	-5%	-$1.63K	0.01%	420
2022 Q3	$34K	Sell	1,088 -1	-0.1%	-$38	0.01%	423
2022 Q2	$59K	Hold	1,089	–	–	0.01%	337
2022 Q1	$59K	Hold	1,089	–	–	0.01%	344
2021 Q4	$60K	Sell	1,089 -30	-3%	-$1.56K	0.01%	338
2021 Q3	$53K	Hold	1,119	–	–	0.01%	344
2021 Q2	$56K	Hold	1,119	–	–	0.01%	335
2021 Q1	$50K	Buy	1,119 +6	+0.5%	+$272	0.01%	334
2020 Q4	$51K	Sell	1,113 -139	-11%	-$6.38K	0.01%	317
2020 Q3	$59K	Hold	1,252	–	–	0.01%	278
2020 Q2	$64K	Hold	1,252	–	–	0.01%	272
2020 Q1	$59K	Hold	1,252	–	–	0.02%	269
2019 Q4	$74K	Buy	1,252 +86	+7%	+$4.78K	0.02%	274
2019 Q3	$62K	Hold	1,166	–	–	0.02%	282
2019 Q2	$58K	Hold	1,166	–	–	0.02%	277
2019 Q1	$61K	Hold	1,166	–	–	0.02%	273
2018 Q4	$56K	Buy	1,166 +161	+16%	+$7.93K	0.02%	258
2018 Q3	$50K	Sell	1,005 -3,398	-77%	-$173K	0.02%	259
2018 Q2	$222K	Hold	4,403	–	–	0.08%	161
2018 Q1	$215K	Sell	4,403 -122	-3%	-$5.68K	0.08%	156
2017 Q4	$201K	Sell	4,525 -2,997	-40%	-$138K	0.07%	158
2017 Q3	$382K	Sell	7,522 -419	-5%	-$21.3K	0.13%	111
2017 Q2	$428K	Sell	7,941 -1,161	-13%	-$61.9K	0.15%	101
2017 Q1	$480K	Sell	9,102 -2,044	-18%	-$104K	0.18%	91
2016 Q4	$537K	Sell	11,146 -2,482	-18%	-$123K	0.25%	90
2016 Q3	$735K	Buy	13,628 +462	+4%	+$25.3K	0.38%	76
2016 Q2	$713K	Buy	13,166 +126	+1%	+$6.64K	0.37%	77
2016 Q1	$661K	Buy	13,040 +178	+1%	+$8.87K	0.35%	76
2015 Q4	$649K	Buy	12,862 +1,832	+17%	+$93.4K	0.38%	70
2015 Q3	$530K	Sell	11,030 -273	-2%	-$14.2K	0.32%	84
2015 Q2	$588K	Buy	11,303 +1,865	+20%	+$105K	0.33%	84
2015 Q1	$544K	Buy	9,438 +8,996	+2,035%	+$516K	0.32%	81
2014 Q4	$30K	Buy	+442	New	+$24.7K	0.02%	209

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Valley National Advisers's GSK Position: Q2 2026 in Review

Valley National Advisers held its GSK (GSK) position steady in Q2 2026 at 1,586 shares worth $83.1K. The position accounts for 0.01% of the portfolio, ranked #346.

Valley National Advisers first reported a position in GSK in Q4 2014 and has held it in 47 quarters since. The position peaked at $735K in Q3 2016. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Valley National Advisers held 1,586 shares of GSK worth $83.1K as of Q2 2026.
Valley National Advisers left its GSK share count unchanged in Q2 2026.
GSK made up 0.01% of Valley National Advisers's portfolio in Q2 2026, its #346 holding.
Valley National Advisers first reported a position in GSK in Q4 2014 and has held it in 47 quarters since.
Valley National Advisers's GSK position peaked at $735K in Q3 2016.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.